{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:54:23Z","timestamp":1772801663248,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T00:00:00Z","timestamp":1488585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40263-017-0416-1","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T19:57:10Z","timestamp":1488571030000},"page":"273-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data"],"prefix":"10.1007","volume":"31","author":[{"given":"Mats O.","family":"Magnusson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie L.","family":"Plan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Niclas","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefaan","family":"Rossenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Russu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,4]]},"reference":[{"key":"416_CR1","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision [DSM-IV-TR]. Arlington (VA): American Psychiatric Association; 2000."},{"issue":"8973","key":"416_CR2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(95)91325-4","volume":"346","author":"NC Andreasen","year":"1995","unstructured":"Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 1995;346(8973):477\u201381.","journal-title":"Lancet"},{"issue":"3","key":"416_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","volume":"67","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453\u201360.","journal-title":"J Clin Psychiatry"},{"key":"416_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0924-977X(15)30724-0","volume":"S2","author":"C Pace Di","year":"2015","unstructured":"Di Pace C, Paletta S, Reggiori A, Maffini M, Chirico M, Mauri MC, Altamura AC. Paliperidone \u201clong-acting\u201d and plasma levels along 1 year of maintenance therapy in schizophrenia and schizoaffective disorder. Eur Neuropsychopharmacol. 2015;S2:525.","journal-title":"Eur Neuropsychopharmacol"},{"key":"416_CR5","unstructured":"US label of INVEGA\u00ae SUSTENNA\u00ae (Revised 01\/2016). Available at: http:\/\/www.invegasustenna.com\/important-product-information . Accessed 10 May 2016."},{"key":"416_CR6","unstructured":"EU label of TREVICTA\u00ae (last updated on eMC 09\/2016). Available at https:\/\/www.medicines.org.uk\/emc\/medicine\/32050 . Accessed 16 Dec 2016."},{"issue":"11","key":"416_CR7","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4088\/JCP.v64n1105","volume":"64","author":"SJ Keith","year":"2003","unstructured":"Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003;64(11):1308\u201315.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"416_CR8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/mp500070m","volume":"11","author":"JF Remenar","year":"2014","unstructured":"Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11(6):1739\u201349.","journal-title":"Mol Pharm"},{"issue":"2","key":"416_CR9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1185\/03007990903482772","volume":"26","author":"S Gopal","year":"2010","unstructured":"Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26(2):377\u201387.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"416_CR10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jcph.597","volume":"56","author":"P Ravenstijn","year":"2016","unstructured":"Ravenstijn P, Remmerie B, Savitz A, De Meulder M, Hough D, Gopal S, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"416_CR11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830\u20139.","journal-title":"JAMA Psychiatry"},{"key":"416_CR12","unstructured":"Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, et al. Population pharmacokinetic modeling of paliperidone palmitate 3-month formulation poster presented at PAGE 24; 2015. Abstr 3408. http:\/\/www.page-meeting.org\/?abstract=3408 ."},{"key":"416_CR13","doi-asserted-by":"crossref","unstructured":"Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, et al. Population pharmacokinetics of a novel once-every 3 months, intramuscular formulation of paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet. 2016. [Epub ahead of print].","DOI":"10.1007\/s40262-016-0459-3"},{"issue":"9","key":"416_CR14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","volume":"48","author":"MN Samtani","year":"2009","unstructured":"Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585\u2013600.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"416_CR15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","volume":"35","author":"G Pandina","year":"2011","unstructured":"Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218\u201326.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"416_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247\u201356.","journal-title":"Int Clin Psychopharmacol"},{"key":"416_CR17","unstructured":"Cirincione B, Redman M, Fiedler-Kelley J, et al. Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia [poster no. PI-21]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 21\u201324 Mar 2007, Anaheim (CA)."},{"key":"416_CR18","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM Users Guides. 1989 Icon development solutions, Ellicott City, Maryland."},{"key":"416_CR19","unstructured":"R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN: 3-900051-07-0. Available at http:\/\/www.R-project.org . Accessed 18 Jan 2016."},{"issue":"10","key":"416_CR20","first-page":"829","volume":"25","author":"MN Samtani","year":"2011","unstructured":"Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25(10):829\u201345.","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"416_CR21","first-page":"85","volume":"81","author":"P Karlsson","year":"2006","unstructured":"Karlsson P, Dencker E, Nyberg S, More L, More JM. Pharmacokinetics, dopamine D2 and serotonin 5 HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Schizophr Res. 2006;81(Suppl. 1):85\u20136.","journal-title":"Schizophr Res"},{"key":"416_CR22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1176\/ajp.153.7.948","volume":"153","author":"S Kapur","year":"1996","unstructured":"Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948\u201350.","journal-title":"Am J Psychiatry"},{"key":"416_CR23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","volume":"33","author":"AL Nordstrom","year":"1993","unstructured":"Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227\u201335.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 3","key":"416_CR24","first-page":"81","volume":"10","author":"S Nyberg","year":"1995","unstructured":"Nyberg S, Nordstrom AL, Halldin C, Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol. 1995;10(Suppl 3):81\u20135.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"416_CR25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","volume":"36","author":"M Vermeir","year":"2008","unstructured":"Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van Osselaer N, Cleton A. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769\u201379.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"416_CR26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5414\/CPP47606","volume":"47","author":"S Boom","year":"2009","unstructured":"Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009;47(10):606\u201316.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"416_CR27","doi-asserted-by":"publisher","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016; 19(7):1\u201314. doi: 10.1093\/ijnp\/pyw018 .","DOI":"10.1093\/ijnp\/pyw018"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0416-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T04:54:28Z","timestamp":1568868868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0416-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,4]]}}}